# EDGAR Filing Document

**Accession Number:** 0001837493
**File Stem:** 0001213900-23-004430
**Filing Date:** 2023-1
**Character Count:** 10279
**Document Hash:** b6a27d89a7d5e0eabf38047c20d506e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-004430.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001213900-23-004430

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230123

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inspira Technologies OXY B.H.N. Ltd
- **CENTRAL INDEX KEY:** 0001837493
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40303
- **FILM NUMBER:** 23544509

**BUSINESS ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504
- **BUSINESS PHONE:** 972-9-9664488

**MAIL ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of January 2023**

**Commission File Number: 001-40303**

**Inspira Technologies Oxy B.H.N. Ltd.**

**(Translation of registrant's name into English)**

**2 Ha-Tidhar St.**

**Ra'anana 4366504, Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**<u>CONTENTS</u>**

On January 23, 2023, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled "Inspira<sup>TM</sup> Technologies Granted Patent by U.S. Patent Office for the INSPIRA<sup>TM</sup> ART System's Convertible Dual Lumen Cannula Design and Method of Use," a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first four and the sixth and seventh paragraphs, and the section titled "Forward-Looking Statements" are incorporated by reference into the Registrant's Registration Statements on [Form F-3](http://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm) (Registration No. 333-266748) and [Form S-8](http://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm) (Registration No. 333-259057), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

| |
|:---|
| **Exhibit No.** |
| 99.1 [Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on January 23, 2023, titled "Inspira<sup>TM</sup> Technologies Granted Patent by U.S. Patent Office for the INSPIRA<sup>TM</sup> ART System's Convertible Dual Lumen Cannula Design and Method of Use."](ea172056ex99-1_inspiratech.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** |
| Date: January 23, 2023 | By: | /s/ Dagi Ben-Noon | /s/ Dagi Ben-Noon |
|  |  | Name: | Dagi Ben-Noon |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Inspira<sup>TM</sup> Technologies Granted Patent by U.S. Patent Office for the INSPIRA<sup>TM</sup> ART System's Convertible Dual Lumen Cannula Device and Method of Use**

<u>All 20 claims were found to be novel, with inventive step and industrial applicability</u>

**Ra'anana, Israel, January 23, 2023 – Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW)** (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the novel convertible dual lumen cannula device and method of use, being developed for the INSPIRA™ ART System, has been granted a patent by the U.S. Patent and Trademark Office (USPTO). The patent approval includes 20 claims that were found to be novel, with inventive step and industrial applicability. Based on the U.S. patent grant, the Company plans to file for similar patents in additional countries.

The Company expects to integrate the convertible dual lumen cannula with additional Inspira products in the future. In addition, the Company may consider the future commercialization of the convertible dual lumen cannula separately as a disposable product.

**An Essential Tool in a Wide Range of Medical Settings**

A dual lumen cannula is a medical disposable device often used for the simultaneous venous drainage and reinfusion of blood during processes such as, but not limited to, extracorporeal membrane oxygenation (ECMO) in Intensive Care Units (ICUs). The dual lumen cannula is a single tube with two separate inner channels or "lumens" and requires only a single incision point.

**Inspira Technologies' Convertible Dual Lumen Cannula**

Inspira Technologies' convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into a dual lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses. The convertible dual lumen cannula is designed to allow for switching from a single lumen to a dual lumen cannula, and vice versa, without the need for new incisions required when changing or adding additional cannulas. The Inspira Technologies convertible dual lumen is designed to potentially allow for fast action and reduced risk, complications and additional infection points.

**CEO of Inspira Technologies, Dagi Ben-Noon:** "The novel, and now patented, convertible dual lumen cannula device represents another step forward in the delivery of new technologies designed to be simple and scalable. In today's market, dual lumens are extremely expensive to manufacture. Therefore, Inspira Technologies believes that the new device can provide the medical market with a more affordable solution, which could contribute to patient safety, procedural efficiency, and reduced risks and complications."

**Enhances Usability and Medical Value of the INSPIRA™ ART System**

The newly patented convertible dual lumen cannula is expected to be a core component of the INSPIRA™ ART system, a potential new mode of acute respiratory care under development, designed to reduce the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing.

The dual lumen cannula device is planned to be utilized during INSPIRA ART treatment with awake patients, potentially facilitating a safer and more comfortable cannulation procedure. For example, by inserting the INSPIRA ART convertible dual lumen in the jugular vein located in the neck, we believe that this will potentially contribute to patient benefits and enhance the INSPIRA ART system's usability and comprehensive medical value to both patients and medical staff.

**Inspira Technologies OXY B.H.N. Ltd.**

Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity. For more information, please visit our corporate website: https://inspira-technologies.com

**Forward-Looking Statement Disclaimer**

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses: the potential benefits to be realized by the newly patented component, including that it may reduce risk, provide the medical market with a more affordable product solution and enhance the INSPIRA ART system's usability and comprehensive medical value to both patients and medical staff; that it expects to integrate the dual lumen cannula with additional products in the future; that it intends to file for additional patents in other countries; and that it may consider the future commercialization of the convertible dual lumen cannula separately as a disposable product. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov

**For more details:**

**US Public Relations**

Dave Gentry<br> RedChip Companies Inc.<br> 1-800-RED-CHIP (733-2447)<br> Or 407-491-4498

IINN@redchip.com

MRK-ARS-050

Copyright© 2018-2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved.